Danaher
$219.679876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$219.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.41 (+0.19%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell Danaher and other stocks, options, and ETFs commission-free!
About DHR
Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC. The listed name for DHR is Danaher Corporation.
CEO
Rainer M. Blair
Employees
60,000
Headquarters
Washington, District of Columbia
Founded
1969
Market Cap
156.78B
Price-Earnings Ratio
45.60
Dividend Yield
0.32
Average Volume
2.50M
High Today
$222.80
Low Today
$219.61
Open Price
$221.62
Volume
3.13M
52 Week High
$248.86
52 Week Low
$119.60
DHR News
Analyst Ratings
86%
of 21 ratings
Buy
86%
Hold
10%
Sell
5%
DHR Earnings
$0.00
$0.69
$1.39
$2.08
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market